Cara Therapeutics to Present Data at Kidney Week 2017
October 16 2017 - 4:01PM
Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company
focused on developing and commercializing new chemical entities
designed to alleviate pain and pruritus by selectively targeting
peripheral kappa opioid receptors, today announced upcoming CR845
presentations at Kidney Week 2017, the American Society of
Nephrology's Annual Meeting, to be held October 31 – November 5,
2017 in New Orleans, LA.
Presentations will include clinical data from a
recently completed Phase 2b trial of I.V. CR845 in hemodialysis
patients suffering from moderate-to-severe pruritus.
Details for the presentations are as
follows:
CR845 Oral Presentation:
Title: |
"Randomized,
Placebo-Controlled Study on the Efficacy of CR845 in Improving the
Quality of Life of Hemodialysis Patients with Chronic Kidney
Disease-Associated Pruritus” |
Abstract Number: |
SA-OR032 |
Date / Time: |
Saturday,
November 4, 2017; 4:42 – 4:54 p.m. CT |
Presenter: |
Frédérique Menzaghi, Ph.D., Senior Vice President,
Research and Development, Cara Therapeutics |
CR845 Poster Presentation:
Poster Title: |
"Randomized,
Placebo-Controlled Study on the Efficacy of CR845 in Reducing
Chronic Kidney Disease-Associated Pruritus in Hemodialysis
Patients" |
Poster Number: |
FR-PO875 |
Date / Time: |
Friday,
November 3, 2017; 9:30 a.m. – 2:30 p.m. CT |
Presenter: |
Robert Spencer, Ph.D., Senior Director, Research
and Development, Cara Therapeutics |
Satellite Symposium:
Title: |
"Pioneering
a Novel Approach to Relieve CKD-Associated Pruritus: Targeting
Peripheral Kappa Opioid Receptors” |
Date / Time: |
Thursday,
November 2, 2017; 10:00 – 11:00 a.m. CT |
Moderator: |
Joseph Stauffer, D.O., M.B.A., Chief Medical
Officer, Cara Therapeutics |
Faculty: |
James A. Tumlin, M.D., F.A.S.N., Director &
Chief Medical Officer, NephroNet, Clinical Trials Consortium;
Founder & Medical Director, Southeast Renal Research Institute;
Professor, Division of Nephrology, University of Tennessee College
of Medicine |
For more information about Kidney Week 2017,
visit https://www.asn-online.org/education/kidneyweek/.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pain and pruritus by
selectively targeting peripheral kappa opioid receptors (KORs).
Cara is developing a novel and proprietary class of product
candidates, led by CR845, a first-in-class KOR agonist that targets
the body's peripheral nervous system. In Phase 2 trials, CR845 has
demonstrated statistically significant reductions in itch intensity
and concomitant improvement in quality of life measures in patients
with moderate-to-severe chronic kidney disease-associated pruritus.
Additionally, CR845 has demonstrated initial signs of efficacy in
patients with moderate-to-severe pain, without inducing many of the
undesirable side effects typically associated with currently
available opioid pain therapeutics.
INVESTOR CONTACT: Michael Schaffzin Stern
Investor Relations, Inc. 212-362-1200 michael@sternir.com
MEDIA CONTACT: Annie Starr 6 Degrees
973-415-8838 astarr@6degreespr.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Sep 2023 to Sep 2024